These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17668482)

  • 1. Death threats for discrepancies over treatment data.
    Burton A
    Lancet Oncol; 2007 Jul; 8(7):577. PubMed ID: 17668482
    [No Abstract]   [Full Text] [Related]  

  • 2. A prostate cancer 'vaccine' under development.
    Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
    [No Abstract]   [Full Text] [Related]  

  • 3. The regulator disapproves.
    Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
    [No Abstract]   [Full Text] [Related]  

  • 4. Fallout from flip-flops.
    Froese P
    Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer vaccine approval could open floodgates.
    Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
    [No Abstract]   [Full Text] [Related]  

  • 6. The Provenge decision.
    DeVita VT
    Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
    [No Abstract]   [Full Text] [Related]  

  • 7. Consultation corner. Prostate cancer vaccine offers new direction.
    Drake C
    Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
    [No Abstract]   [Full Text] [Related]  

  • 8. Concerns about Provenge simmer as CMS ponders coverage.
    Goozner M
    J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
    [No Abstract]   [Full Text] [Related]  

  • 9. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 10. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.
    Baghdadi R
    Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168
    [No Abstract]   [Full Text] [Related]  

  • 11. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Sartor O
    BJU Int; 2012 Jul; 110(2 Pt 2):E105. PubMed ID: 22176510
    [No Abstract]   [Full Text] [Related]  

  • 12. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
    Chambers JD; Neumann PJ
    N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
    [No Abstract]   [Full Text] [Related]  

  • 13. The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.
    Bot A
    Int Rev Immunol; 2010 Jun; 29(3):235-8. PubMed ID: 20521923
    [No Abstract]   [Full Text] [Related]  

  • 14. Continuous improvement versus innovation: the case for sipuleucel-T.
    Tombal B
    Eur Urol; 2012 Apr; 61(4):648-9; discussion 650-1. PubMed ID: 22154024
    [No Abstract]   [Full Text] [Related]  

  • 15. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
    Goodman AJ
    J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
    [No Abstract]   [Full Text] [Related]  

  • 16. Is Provenge Angst a symbol or symptom of the times?
    Holcombe DG
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274
    [No Abstract]   [Full Text] [Related]  

  • 17. How does sipuleucel-T alter our clinical practice?
    George D
    BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
    [No Abstract]   [Full Text] [Related]  

  • 18. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
    Becze E
    ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Drake CG
    J Natl Cancer Inst; 2012 Sep; 104(18):1422; author reply 1422-3. PubMed ID: 22911668
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Kantoff PW; Higano CS; Small EJ; Whitmore JB; Frohlich MW; Schellhammer PF
    J Natl Cancer Inst; 2012 Jul; 104(14):1107-9; author reply 1109-12. PubMed ID: 22825556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.